Avalanche Biotech (NASDAQ:AAVL)Shares of Avalanche Biotech fell as much as 40% in after-hours trading on June 15, 2015 after the company announced results from its phase 2 wet-age related macular degeneration — wet-AMD — trial. The drop is huge but many investors should be assured that the drop was justified because the results were mediocre at best. In addition if […]
Biotech stocks can often make big moves after reporting trial data, but it’s FDA drug approvals or denials that can really make stocks in the industry pop or drop. For that reason, we asked three Motley Fool experts what FDA decisions they’re most excited about. Read on to learn which three companies and drugs are on their radar.Source: Celgene Corporation.: […]
Source: Flickr user stockmonkeys.com .The pop-and-drop nature of the biotech industry makes owning stocks in the sector particularly dicey. But for investors willing to take on the risk of failure, a number of intriguing small-cap biotech companies are working on important new therapies that could make a big impact on patients’ lives and investors’ wallets. Here are three of thesecompanies.No. […]
Source: Biogen IdecAs the year begins to come to a close, biotechnology investors are right to wonder what stocks may be worth owning as we head into 2015. We asked three of our Motley Fool analysts to tell us which three biotechnology stocks will be in their stockings this holiday season. Read on to see which three companies they chose.Cheryl […]
Last week, earnings remained in focus with several companies reporting their third quarter results. While AbbVie’s (ABBV – Analyst Report) results remained strong with the company raising its outlook, companies like Regeneron (REGN – Analyst Report) and Aegerion (AEGR – Analyst Report) narrowed their sales outlooks for their key products.Among all this, Geron (GERN – Analyst Report) made it to […]
